Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord blood (Bundang CHA Hospital)
- Development stage
- Unknown
- Lead developer
- CHA Bundang Medical Center
- Modality
- Stem Cell Therapies → Cell Therapies, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
An investigational cell therapy regimen developed by Bundang CHA Hospital for the treatment of subacute stroke. The therapy consists of allogeneic umbilical cord blood (UCB) cells, matched for human leukocyte antigens (HLA-A, B, and DR) and sourced from the CHA Cord Blood Bank. In clinical development (e.g., NCT04013646), the UCB infusion is administered as a single intravenous dose, often in combination with recombinant human erythropoietin (rhEPO) to enhance therapeutic outcomes. The biological mechanism involves the neuroprotective, neuroregenerative, and anti-inflammatory properties of the cord blood cells, while the erythropoietin component is intended to synergistically promote angiogenesis and neurogenesis via the erythropoietin receptor. The treatment is targeted at patients in the subacute phase of stroke, typically one to nine months post-onset, to facilitate neurological recovery and functional improvement.
- Other names
- umbilical cord blood-Bundang CHA Hospital-strokeUCB therapyumbilical cord blood infusionallogeneic umbilical cord blood
Beyond the preview
Go deeper on allogeneic umbilical cord blood (Bundang CHA Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord blood (Bundang CHA Hospital).